Angela Dispenzieri
Overview
Explore the profile of Angela Dispenzieri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
815
Citations
26972
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muchtar E, Dispenzieri A, Sanchorawala V, Hassan H, Mwangi R, Maurer M, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 39994333
Autologous stem cell Transplant (ASCT)-related mortality (TRM) in AL amyloidosis remains elevated. AL amyloidosis patients (n = 1718) from 9 centers, transplanted 2003-2020 were included. Pre-ASCT variables of interest were...
2.
Dorbala S, Adigun R, Alexander K, Brambatti M, Cuddy S, Dispenzieri A, et al.
JACC Cardiovasc Imaging
. 2025 Feb;
PMID: 39985507
Light chain amyloidosis and transthyretin amyloidosis are rare protein misfolding disorders characterized by amyloid deposition in organs, varied clinical manifestations, and poor outcomes. Amyloid fibrils trigger various signaling pathways that...
3.
Rees M, Muchtar E, Atallah-Yunes S, Dasari S, Leung N, Gertz M, et al.
Amyloid
. 2025 Feb;
:1-3.
PMID: 39972595
No abstract available.
4.
Zanwar S, Jevremovic D, Kapoor P, Olteanu H, Buadi F, Horna P, et al.
Blood Cancer J
. 2025 Feb;
15(1):20.
PMID: 39966346
Risk stratification models based on cytogenetics and disease burden help identify high-risk patients with newly diagnosed multiple myeloma (NDMM). However, some high-risk patients remain undetected. This study evaluated the prognostic...
5.
Pierson S, Brandstadter J, Torigian D, Bagg A, Lechowicz M, Alapat MD D, et al.
Blood Adv
. 2025 Feb;
PMID: 39951615
Castleman disease (CD) describes a group of rare lymphoproliferative disorders that exhibit a wide range of symptomatology and degree of lymphadenopathy, particularly across the two forms of CD with unknown...
6.
De Michieli L, AbouEzzeddine O, Abbasi M, Davies D, Scott C, Muchtar E, et al.
JACC CardioOncol
. 2025 Feb;
7(1):70-78.
PMID: 39896120
Background: Technetium Tc 99m pyrophosphate scintigraphy (Tc PYP imaging) is a diagnostic tool for transthyretin amyloid cardiomyopathy (ATTR-CM). Cardiac biomarkers, particularly high-sensitivity cardiac troponin (hs-cTn) and N-terminal pro-B-type natriuretic peptide...
7.
Charalampous C, Claveau J, Kapoor P, Binder M, Buadi F, Cook J, et al.
Blood Adv
. 2025 Jan;
PMID: 39883947
In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic...
8.
Adams D, Wixner J, Polydefkis M, Berk J, Conceicao I, Dispenzieri A, et al.
JAMA Neurol
. 2025 Jan;
82(3):228-236.
PMID: 39804640
Importance: There is a lack of long-term efficacy and safety data on hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and on RNA interference (RNAi) therapeutics in general. This study presents the...
9.
Lyle M, Farina J, Wiedmeier-Nutor E, Lindpere V, Klanderman M, Nativi-Nicolau J, et al.
Clin Transplant
. 2025 Jan;
39(1):e70070.
PMID: 39775986
Background: The prognosis in patients with advanced cardiac amyloidosis (CA) remains poor. Objectives: We sought to describe survival post heart transplantation (HT) in amyloid compared with non-amyloid recipients, highlight waitlist...
10.
Netzel B, Charlesworth M, Johnson K, French A, Dispenzieri A, Maleszewski J, et al.
Amyloid
. 2025 Jan;
32(1):72-80.
PMID: 39773246
Background: Cardiac AL and ATTR are potentially fatal cardiomyopathies. Current therapies do not address mechanisms of tissue dysfunction because these remain unknown. Our prior work focused on the amyloid plaque...